Search

Your search keyword '"Mawlawi, O.R."' showing total 19 results
Start Over Author "Mawlawi, O.R."
19 results on '"Mawlawi, O.R."'

3. Importance of PET-CT Radiomics Features in Outcomes Prognostication for Mediastinal Hodgkin Lymphoma

Author

Milgrom, S.A., primary, Lee, J.S., additional, Wang, Q., additional, Court, L.E., additional, Ng, A., additional, Pinnix, C.C., additional, Dabaja, B., additional, Akhtari, M., additional, Aristophanous, M., additional, Mawlawi, O.R., additional, Andraos, T.Y., additional, Lee, H., additional, Hagemeister, F., additional, Oki, Y., additional, Fanale, M.A., additional, Sulman, E.P., additional, and Smith, G.L., additional

Published
2017
Full Text
View/download PDF

4. Restratifying Early-Stage Hodgkin Lymphoma Patients Using Novel Functional Imaging Parameters

Author

Akhtari, M., primary, Reddy, J., additional, Dong, W., additional, Milgrom, S.A., additional, Smith, G.L., additional, Pinnix, C.C., additional, Yehia, Z. Abou, additional, Gunther, J.R., additional, Osborne, E.M., additional, Mawlawi, O.R., additional, Rohren, E.M., additional, Chuang, H.H., additional, Garg, N., additional, Fanale, M., additional, and Dabaja, B., additional

Published
2016
Full Text
View/download PDF

5. Utilization of Positron Emission Tomography/Computed Tomography Parameters to Identify Patients at Risk for Progression After Treatment With Dose-Adjusted R-EPOCH for Primary Mediastinal B-Cell Lymphoma (PMBCL)

Author

Pinnix, C.C., primary, Yehia, Z. Abou, additional, Qiao, W., additional, Milgrom, S.A., additional, Smith, G.L., additional, Akhtari, M., additional, Reddy, J., additional, Gunther, J.R., additional, Osborne, E.M., additional, Mawlawi, O.R., additional, Medeiros, L.J., additional, Garg, N., additional, Chuang, H.H., additional, Neelapu, S., additional, Westin, J.R., additional, and Dabaja, B., additional

Published
2016
Full Text
View/download PDF

6. Prognostic Significance of the Postchemotherapy Positron Emission Tomography (PET)/Computed Tomography in Early-Stage Hodgkin Lymphoma: Can PET-Positive Patients Be Cured With Radiation Alone?

Author

Milgrom, S.A., primary, Smith, G.L., additional, Pinnix, C.C., additional, Dong, W., additional, Akhtari, M., additional, Mawlawi, O.R., additional, Rohren, E.M., additional, Garg, N., additional, Chuang, H.H., additional, Reddy, J., additional, Gunther, J.R., additional, Osborne, E.M., additional, Yehia, Z. Abou, additional, Oki, Y., additional, Fanale, M., additional, and Dabaja, B., additional

Published
2016
Full Text
View/download PDF

7. Postchemotherapy Positron Emission Tomography/Computed Tomography Scans in Early-Stage Hodgkin Lymphoma: Moving Beyond the Deauville 5-Point Scale

Author

Milgrom, S.A., primary, Dong, W., additional, Akhtari, M., additional, Smith, G.L., additional, Pinnix, C.C., additional, Mawlawi, O.R., additional, Rohren, E.M., additional, Garg, N., additional, Chuang, H.H., additional, Yehia, Z. Abou, additional, Reddy, J., additional, Gunther, J.R., additional, Osborne, E.M., additional, Oki, Y., additional, Fanale, M., additional, and Dabaja, B., additional

Published
2016
Full Text
View/download PDF

9. Effectiveness of Radiation Treatment in Adult Patients With Mediastinal T Cell Lymphoblastic Leukemia/Lymphoma

Author

Abou Yehia, Z., primary, Dabaja, B., additional, Smith, G.L., additional, Milgrom, S.A., additional, Kantarjian, H., additional, Allen, P.K., additional, Garg, N., additional, Pierce, S.A., additional, Reddy, J., additional, Mawlawi, O.R., additional, Suki, T., additional, Medeiros, L.J., additional, Jabbour, E., additional, Jain, N., additional, and Pinnix, C.C., additional

Published
2016
Full Text
View/download PDF

11. Use of Emission Guided Radiation Therapy Can Better Spare Critical Structures Compared With Intensity Modulated Radiation Therapy, Volumetric Modulated Arc Therapy, or Proton Therapy

Author

Seyedin, S.N., primary, Mawlawi, O.R., additional, Turner, L.M., additional, Mazin, S., additional, Voronenko, Y., additional, Olcott, P.D., additional, Wages, C.A., additional, Balter, P., additional, Chang, J.Y., additional, Gomez, D.R., additional, Komaki, R.U., additional, and Welsh, J.W., additional

Published
2015
Full Text
View/download PDF

19. A Prospective Pilot Study Investigating 18F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Prostatectomy.

Author

Surasi, D.S., Bathala, T., Choi, S., Shah, S.J., Nguyen, Q.N., Hoffman, K.E., Mayo, L.L., Mok, H., Frank, S.J., Fang, A., Sheth, R., Hwang, K.P., Mawlawi, O.R., Macapinlac, H., Troncoso, P., Zhang, M., Pasyar, S., Bassett, R., Chapin, B., and Tang, C.

Subjects
*MAGNETIC resonance imaging, *PROSTATE cancer, *GLEASON grading system, *LIGANDS (Biochemistry), *SALVAGE therapy, *HORMONE therapy, *RADIOTHERAPY
Abstract

Simultaneous PET/MRI imaging has the advantage of combining metabolic information from PET with the high-spatial resolution of MRI to identify disease with greater accuracy than conventional imaging. F-18 rhPSMA 7.3 (rhPSMA) ligands are a new class of diagnostic/therapeutic PSMA-targeting agents in prostate cancer (PCa). We hypothesized that F-18 rhPSMA 7.3 PET/MRI accurately detects recurrent PCa to direct field design in salvage radiation therapy (RT) planning even at low PSA levels. This is a prospective phase II pilot study enrolling men with biochemical recurrence (BCR) after prostatectomy for PCa who underwent rhPSMA 7.3 PET on a simultaneous 3T PET/MRI scanner. The radiation oncologists answered surveys to document changes to RT plan based on the PET/MRI results. All patients underwent standard fractionated RT with at least 6 months of hormonal therapy (HR). Patients with positive scan returned 6-18 months after the first scan for a second timepoint PET/MRI scan after treatment. Standard of truth was established by pathology when feasible or a combination of confirmatory imaging showing radiographic and PSA response after treatment. The primary aim is to evaluate the positive predictive value (PPV) of rhPSMA PET/MRI in detecting disease. The secondary aims included change in RT plan after rhPSMA PET/MRI and treatment response. 29 patients with a median age of 66 years (IQR: 47-76) at the time of imaging were enrolled between Aug 2021 to Jan 2023, of which 28 patients underwent rhPSMA PET/MRI scan. The Gleason score at diagnosis was ≥7 with a median PSA of 7.0 ng/mL (IQR: 0.9-29.5) before surgery. Median PSA was 0.3 ng/mL (IQR: 0.2-1.5) at BCR presentation with 24 (86%) patients having PSA <0.5. Twenty patients (71%) had rhPSMA positive findings. 4/20 patients with rhPSMA positive lesions did not receive follow up imaging as they chose to undergo treatment elsewhere. Of the 16 patients who underwent a confirmatory scan and/or biopsy, 15/16 (94%) patients were found to be true positive while 1/16 (6%) was a false positive. RT plan was changed in 22/28 (79%) with major changes including extension of clinical target volumes to cover PSMA positive pelvic lesions or cancellation of RT due to polymetastatic disease in 8/22 (36%), minor changes including dose escalation to gross disease or dose de-escalation to the rest of prostate fossa in 9/22 (41%) and both major and minor changes in 5/22 (23%) patients. All 14 patients who underwent a combination of RT and HT had complete response on the second timepoint rhPSMA PET/MRI. Median PSA was <0.1 ng/mL (IQR: <0.1-0.1) ng/mL after treatment before the second scan. Even at low PSA levels, F-18 rhPSMA 7.3 PET/MRI resulted in a high detection rate of true positive lesions. Furthermore, incorporation of this technology led to changes in 79% of RT plans. Simultaneous F-18 rhPSMA 7.3 PET/MRI imaging can potentially serve as a "one stop shop" to stratify patient treatment and tailor salvage radiation fields. (NCT04978675) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results